Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
NYSE:AGE

AgeX Therapeutics - AGE Stock Forecast, Price & News

$0.60
0.00 (0.00%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.60
▼
$0.60
50-Day Range
$0.55
▼
$0.69
52-Week Range
$0.52
▼
$1.39
Volume
811 shs
Average Volume
21,015 shs
Market Capitalization
$22.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AGE stock logo

About AgeX Therapeutics (NYSE:AGE) Stock

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGE Stock News Headlines

November 25, 2022 | finance.yahoo.com
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
November 10, 2022 | finance.yahoo.com
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
October 12, 2022 | marketwatch.com
Longevity and Anti-senescence Therapy Market Analysis Research Report, Challenges, Scopes, Market Share, Revenue, and Forecasts 2022 to 2028
September 12, 2022 | finance.yahoo.com
AgeX Therapeutics, Inc. (AGE)
August 14, 2022 | seekingalpha.com
AgeX Therapeutics GAAP EPS of -$0.07, revenue of $0.01M
August 14, 2022 | marketwatch.com
AgeX Therapeutics Says Its Cash Position Raises Doubt About Continuing as a Going Concern
August 12, 2022 | finance.yahoo.com
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
August 11, 2022 | forbes.com
The 9th ARDD: Longevity Biotechnology Is Gaining Prominence And Credibility In The Pharmaceutical Industry
May 18, 2022 | finance.yahoo.com
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
May 15, 2022 | seekingalpha.com
AgeX Therapeutics GAAP EPS of -$0.07
May 13, 2022 | finance.yahoo.com
AgeX Therapeutics Reports First Quarter 2022 Financial Results
April 14, 2022 | uk.finance.yahoo.com
Global Senolytic Drugs Market, By Type, By Application, By Distribution Channel, By Region, Competition Forecast and Opportunities, 2017-2027
March 31, 2022 | seekingalpha.com
AgeX Therapeutics GAAP EPS of -$0.23, revenue of $0.14M
March 29, 2022 | finance.yahoo.com
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
February 1, 2022 | nasdaq.com
AgeX Therapeutics, Inc. Common Stock (AGE)
January 15, 2022 | nasdaq.com
AgeX Therapeutics Inc. Shares Close the Week 25.5% Lower - Weekly Wrap
January 15, 2022 | nasdaq.com
AgeX Therapeutics Inc. Shares Close the Day 12.5% Lower - Daily Wrap
December 14, 2021 | finance.yahoo.com
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
November 30, 2021 | finance.yahoo.com
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
November 12, 2021 | finance.yahoo.com
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
October 9, 2021 | nasdaq.com
AgeX Therapeutics Inc. Shares Near 52-Week Low - Market Mover
August 13, 2021 | finance.yahoo.com
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
July 23, 2021 | msn.com
BRIEF-Agex Therapeutics And Lygenesis Terminate Merger Negotiations
July 23, 2021 | marketwatch.com
AgeX Therapeutics, LyGenesis End Merger Talks
July 23, 2021 | finance.yahoo.com
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
See More Headlines
Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGE Company Calendar

Today
11/27/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:AGE
CUSIP
N/A
CIK
1708599
Web
www.agexinc.com
Phone
(510) 671-8370
Fax
510-871-4154
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,680,000.00
Net Margins
-18,711.33%
Pretax Margin
-18,911.33%
Return on Equity
N/A
Return on Assets
-383.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.13
Quick Ratio
0.13

Sales & Book Value

Annual Sales
$140,000.00
Price / Sales
162.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.40) per share
Price / Book
-1.50

Miscellaneous

Outstanding Shares
37,950,000
Free Float
35,655,000
Market Cap
$22.78 million
Optionable
Not Optionable
Beta
1.43

Key Executives

  • Dr. Michael D. West Ph.D. (Age 69)
    Founder, Pres, CEO & Director
    Comp: $561.28k
  • Ms. Eun-Jae Park CPA (Age 50)
    Chief Financial Officer
    Comp: $279.32k
  • Dr. Nafees Naseer Malik M.D. (Age 44)
    Chief Operating Officer
    Comp: $282.27k
  • Dr. Ivan Labat
    Chief Information Officer
  • Ms. Judith Segall (Age 69)
    Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













AGE Stock - Frequently Asked Questions

How have AGE shares performed in 2022?

AgeX Therapeutics' stock was trading at $1.09 at the beginning of 2022. Since then, AGE shares have decreased by 44.9% and is now trading at $0.6003.
View the best growth stocks for 2022 here.

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), Ampio Pharmaceuticals (AMPE), AzurRx BioPharma (AZRX) and Digital Ally (DGLY).

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

Who are AgeX Therapeutics' major shareholders?

AgeX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Strategic Wealth Investment Group LLC (0.22%).
View institutional ownership trends.

How do I buy shares of AgeX Therapeutics?

Shares of AGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $0.60.

How much money does AgeX Therapeutics make?

AgeX Therapeutics (NYSE:AGE) has a market capitalization of $22.78 million and generates $140,000.00 in revenue each year.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 965 ATLANTIC AVENUE SUITE 101, ALAMEDA CA, 94501. The official website for the company is www.agexinc.com. The company can be reached via phone at (510) 671-8370 or via fax at 510-871-4154.

This page (NYSE:AGE) was last updated on 11/27/2022 by MarketBeat.com Staff